Transarterial chemoembolization (TACE) plus apatinib vs. TACE alone for hepatocellular carcinoma - 05/11/22
Edited by: R. Poupon
Highlights |
• | TACE plus apatinib increased overall response than TACE. |
• | TACE plus apatinib elevated PFS but not OS than TACE. |
• | TACE plus apatinib did not affect liver function indexes. |
• | TACE plus apatinib increased HFSR incidence but not other AEs than TACE. |
Abstract |
Objective |
Transarterial chemoembolization (TACE) is a common therapy for hepatocellular carcinoma (HCC), while TACE-induced tumor angiogenesis would increase progression and metastasis risk. Besides, apatinib possesses the capability of inhibiting tumor angiogenesis. Thus, this study aimed to explore the efficacy and safety of TACE plus apatinib compared to TACE alone in HCC patients.
Methods |
Ninety-six intermediate-advanced HCC patients were retrospectively enrolled and classified into TACE plus apatinib group (N = 45) and TACE group (N = 51) based on the treatment.
Results |
Objective response rate (68.9% vs. 47.1%) was increased in TACE plus apatinib group than in TACE group (P = 0.031). However, no difference was found in disease-control rate between groups (95.6% vs. 86.3%) (P = 0.167). Progression-free survival (PFS) (median PFS (95% confidence interval (CI)): 20.0 (13.2–26.8) vs. 14.0 (8.3–19.7) months) was enhanced in TACE plus apatinib group compared with TACE group (P = 0.030), while no difference was found in overall survival between groups (P = 0.060). Additionally, multivariate Cox's analysis presented that TACE plus apatinib (vs. TACE alone) independently associated with prolonged PFS (P = 0.043, hazard ratio = 0.617). Regarding safety profile, no difference in liver function indexes (albumin, total bilirubin, alanine aminotransferase and aspartate aminotransferase) was found after treatment between two groups; meanwhile, only the incidence of hand-foot skin reaction (24.4% vs. 7.8%) was higher in TACE plus apatinib group compared to TACE group (P = 0.025), while no difference was found in other adverse events between two groups (all P > 0.05).
Conclusion |
TACE plus apatinib illustrates a superior efficacy with tolerable safety than TACE alone in intermediate-advanced HCC patients.
Le texte complet de cet article est disponible en PDF.Keywords : Hepatocellular carcinoma, Transarterial chemoembolization, Apatinib, Therapeutic efficacy, Safety profile
Plan
| Ningjie Li and Ping Yang contributed equally to this work. |
Vol 46 - N° 9
Article 102022- novembre 2022 Retour au numéro
Article précédent
- ATP-binding cassette transporters expression in rats with cirrhosis and hepatic encephalopathy
- Charlotte Bouzbib, Haquima El Mourabit, Dominique Wendum, Elisabeth Lasnier, Sarah Mouri, Chantal Housset, Dominique Thabut, Nicolas Weiss, Marika Rudler
- HCV eradication does not protect from fibrosis progression in patients with fibrosing cholestatic hepatitis after liver transplantation
- Audrey Coilly, Mylène Sebagh, Claire Fougerou-Leurent, Georges-Philippe Pageaux, Vincent Leroy, Sylvie Radenne, Christine Silvain, Pascal Lebray, Pauline Houssel-Debry, Carole Cagnot, Emilie Rossignol, Hélène Danjou, Aurélie Veislinger, Didier Samuel, Jean-Charles Duclos-Vallée, Jérôme Dumortier
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?